desloratadine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histamine-H1 receptor antagonists, tricyclic compounds 814 100643-71-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • SCH-34117
  • SCH 34117
  • desloratadine
  • azomyr
  • delopedil
  • descarboethoxyloratadine
  • descarboethoxyloratidine
  • neoclarityn
major metabolite of loratadine
  • Molecular weight: 310.83
  • Formula: C19H19ClN2
  • CLOGP: 3.83
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 24.92
  • ALOGS: -4.90
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.23 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 2001 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 148.22 12.34 109 14434 41967 53292556
Urticaria 131.31 12.34 173 14370 135712 53198811
Drug reaction with eosinophilia and systemic symptoms 55.76 12.34 56 14487 32744 53301779
Rheumatoid arthritis 54.45 12.34 10 14533 314521 53020002
Allergy test positive 54.26 12.34 14 14529 381 53334142
Erythema 53.11 12.34 126 14417 156843 53177680
Pruritus 49.50 12.34 184 14359 293648 53040875
Toxic skin eruption 46.13 12.34 34 14509 13105 53321418
Hyponatraemia 44.35 12.34 94 14449 108513 53226010
Intentional self-injury 42.66 12.34 43 14500 25241 53309282
Dermatitis bullous 42.64 12.34 27 14516 8136 53326387
Hallucination, auditory 42.54 12.34 31 14512 11742 53322781
Death 39.95 12.34 24 14519 357208 52977315
Haemangioma congenital 37.40 12.34 11 14532 491 53334032
Paranoia 32.31 12.34 26 14517 11398 53323125
Eczema 31.74 12.34 36 14507 24146 53310377
Terminal dribbling 31.44 12.34 6 14537 37 53334486
Blood immunoglobulin E increased 30.38 12.34 14 14529 2241 53332282
Gestational hypertension 29.93 12.34 14 14529 2319 53332204
Victim of chemical submission 29.61 12.34 8 14535 261 53334262
Intentional overdose 28.38 12.34 59 14484 67146 53267377
Completed suicide 27.12 12.34 3 14540 138198 53196325
Cerebral thrombosis 26.89 12.34 12 14531 1783 53332740
Face oedema 26.34 12.34 30 14513 20210 53314313
Drug intolerance 25.60 12.34 12 14531 205481 53129042
Oxalosis 25.53 12.34 5 14538 36 53334487
Tooth injury 25.26 12.34 10 14533 1103 53333420
Type IV hypersensitivity reaction 25.11 12.34 13 14530 2679 53331844
Skin dystrophy 24.85 12.34 5 14538 42 53334481
Aggression 24.41 12.34 31 14512 23372 53311151
Urticaria thermal 23.86 12.34 6 14537 147 53334376
Somnolence 23.30 12.34 99 14444 167635 53166888
Burn oral cavity 21.95 12.34 5 14538 79 53334444
Hyperkalaemia 21.02 12.34 46 14497 54210 53280313
Hyperoxaluria 19.82 12.34 5 14538 124 53334399
Joint swelling 19.64 12.34 21 14522 234617 53099906
Synovitis 19.59 12.34 3 14540 107890 53226633
Tongue oedema 19.55 12.34 13 14530 4254 53330269
Dermatitis exfoliative generalised 19.48 12.34 12 14531 3443 53331080
Nasal ulcer 19.00 12.34 9 14534 1533 53332990
Inflammatory bowel disease 18.51 12.34 12 14531 3761 53330762
Treatment failure 18.45 12.34 6 14537 128397 53206126
Guttate psoriasis 18.40 12.34 6 14537 378 53334145
Asthma 18.07 12.34 68 14475 108904 53225619
Keratopathy 17.88 12.34 6 14537 413 53334110
Systemic lupus erythematosus 17.78 12.34 6 14537 125408 53209115
Nightmare 17.70 12.34 23 14520 17728 53316795
HLA-B*27 positive 17.34 12.34 5 14538 208 53334315
Hepatocellular injury 17.20 12.34 30 14513 29956 53304567
Urine oxalate increased 17.16 12.34 5 14538 216 53334307
Photosensitivity reaction 17.15 12.34 20 14523 13808 53320715
Rash erythematous 17.02 12.34 34 14509 37589 53296934
Drug ineffective 16.61 12.34 143 14400 817102 52517421
Acute kidney injury 16.47 12.34 122 14421 253746 53080777
Pain 16.32 12.34 94 14449 588304 52746219
Upper respiratory tract infection bacterial 16.31 12.34 4 14539 88 53334435
Arteriospasm coronary 16.09 12.34 11 14532 3766 53330757
Rash maculo-papular 16.08 12.34 29 14514 29720 53304803
Eosinophilia 15.85 12.34 24 14519 21311 53313212
Wound 15.62 12.34 3 14540 91554 53242969
Abortion 15.37 12.34 9 14534 2357 53332166
Patent ductus arteriosus 15.23 12.34 11 14532 4107 53330416
Arrhythmia 15.18 12.34 32 14511 36747 53297776
Amnestic disorder 15.05 12.34 5 14538 334 53334189
Psychotic disorder 14.78 12.34 25 14518 24360 53310163
Feeling hot 14.72 12.34 34 14509 41510 53293013
Hypersensitivity pneumonitis 14.68 12.34 9 14534 2561 53331962
Pharyngeal oedema 14.67 12.34 19 14524 14594 53319929
Nasal pruritus 14.48 12.34 5 14538 376 53334147
Lip oedema 14.18 12.34 10 14533 3597 53330926
Vitamin D deficiency 14.01 12.34 17 14526 12231 53322292
Subretinal haematoma 13.94 12.34 3 14540 36 53334487
Systolic hypertension 13.82 12.34 5 14538 431 53334092
Vertigo 13.78 12.34 40 14503 56041 53278482
Intraocular haematoma 13.51 12.34 3 14540 42 53334481
Pancoast's syndrome 13.32 12.34 3 14540 45 53334478
Therapeutic product effect decreased 13.25 12.34 9 14534 125646 53208877
Drug dose titration not performed 13.23 12.34 5 14538 487 53334036
Eyelid erosion 13.20 12.34 3 14540 47 53334476
Fixed eruption 13.18 12.34 6 14537 934 53333589
White blood cell count decreased 13.01 12.34 9 14534 124466 53210057
Hernia hiatus repair 12.91 12.34 3 14540 52 53334471
Parkinsonism 12.82 12.34 14 14529 8999 53325524
Hepatic lesion 12.74 12.34 10 14533 4227 53330296
Anaphylactic shock 12.68 12.34 22 14521 21871 53312652
Disease progression 12.60 12.34 6 14537 101914 53232609
Hepatic cytolysis 12.55 12.34 13 14530 7872 53326651
Renal tubular atrophy 12.49 12.34 5 14538 568 53333955
Urticaria chronic 12.44 12.34 5 14538 574 53333949
Product use in unapproved indication 12.40 12.34 62 14481 112227 53222296

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eosinophilia 59.43 14.86 48 7495 24910 32481073
Pruritus 53.51 14.86 102 7441 128600 32377383
Rash maculo-papular 50.61 14.86 46 7497 27976 32478007
Toxic skin eruption 49.94 14.86 32 7511 11582 32494401
Dermatitis bullous 49.38 14.86 26 7517 6527 32499456
Death 42.36 14.86 18 7525 382499 32123484
Hepatic haematoma 39.35 14.86 11 7532 482 32505501
Intentional overdose 38.75 14.86 48 7495 41553 32464430
Eczema 38.19 14.86 30 7513 14950 32491033
Urticaria 37.68 14.86 57 7486 59557 32446426
Xerosis 37.64 14.86 11 7532 566 32505417
Hyperkaliuria 34.45 14.86 8 7535 164 32505819
Corneal abscess 33.15 14.86 6 7537 32 32505951
Electrocardiogram QT prolonged 31.06 14.86 42 7501 39599 32466384
Miosis 27.90 14.86 20 7523 8684 32497299
Rash pustular 26.36 14.86 16 7527 5263 32500720
Keratitis 25.61 14.86 10 7533 1252 32504731
Angioedema 24.78 14.86 36 7507 36253 32469730
Purpura 24.52 14.86 20 7523 10505 32495478
Blood immunoglobulin E decreased 24.35 14.86 5 7538 56 32505927
Oedema genital 22.96 14.86 7 7536 417 32505566
Prurigo 22.68 14.86 8 7535 754 32505229
Bulbar palsy 21.53 14.86 6 7537 260 32505723
Eyelid ptosis congenital 21.51 14.86 5 7538 103 32505880
Type III immune complex mediated reaction 21.39 14.86 6 7537 266 32505717
Arrhythmia 21.22 14.86 33 7510 35270 32470713
Pemphigoid 19.59 14.86 16 7527 8420 32497563
Dermatitis psoriasiform 19.03 14.86 8 7535 1210 32504773
Myoglobin blood increased 18.74 14.86 9 7534 1858 32504125
Asthma 18.34 14.86 35 7508 44030 32461953
Rash erythematous 18.19 14.86 25 7518 23914 32482069
Retinopathy 17.71 14.86 9 7534 2098 32503885
Vasoplegia syndrome 17.67 14.86 8 7535 1446 32504537
Purulent pericarditis 17.28 14.86 3 7540 12 32505971
Rhabdomyolysis 17.27 14.86 44 7499 67221 32438762
Rhinitis allergic 17.20 14.86 10 7533 3039 32502944
Wrong product administered 17.16 14.86 12 7531 5008 32500975
Hyperlipasaemia 17.16 14.86 6 7537 551 32505432
Hypertrophic cardiomyopathy 17.10 14.86 7 7536 991 32504992
Poisoning deliberate 16.75 14.86 13 7530 6362 32499621
Spermatic cord disorder 16.74 14.86 3 7540 15 32505968
Dermatitis exfoliative 16.71 14.86 14 7529 7630 32498353
Coma 16.70 14.86 33 7510 42579 32463404
Wrong patient received product 16.39 14.86 9 7534 2453 32503530
Acute generalised exanthematous pustulosis 16.32 14.86 13 7530 6600 32499383
Cerebral venous thrombosis 16.25 14.86 6 7537 645 32505338
Intentional self-injury 16.19 14.86 18 7525 13882 32492101
Neonatal pneumonia 15.46 14.86 4 7539 130 32505853
Pemphigus 15.01 14.86 7 7536 1355 32504628

Pharmacologic Action:

SourceCodeDescription
ATC R06AX27 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
FDA MoA N0000000190 Histamine H1 Receptor Antagonists
FDA EPC N0000175587 Histamine-1 Receptor Antagonist
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D039563 Histamine H1 Antagonists, Non-Sedating
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:37955 H1-receptor blockers
CHEBI has role CHEBI:48873 Anticholinergika
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:50857 anti-allergic agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Vasomotor rhinitis indication 8229003 DOID:4730
Allergic urticaria indication 40178009 DOID:10612
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Common cold indication 82272006 DOID:10459
Chronic idiopathic urticaria indication 302162004
Seasonal allergic rhinitis indication 367498001
Allergic conjunctivitis indication 473460002 DOID:11204
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Hypertensive urgency contraindication 443482000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 2.48 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.91 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.96 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 8.03 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.55 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.80 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.00 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.01 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.19 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.97 DRUG MATRIX
Histamine H4 receptor GPCR IC50 4.80 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 7.74 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 7.60 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 7.49 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 7.70 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 7.30 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.51 DRUG MATRIX
Multidrug resistance protein 1 Transporter IC50 4.37 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 5.70 DRUG MATRIX

External reference:

IDSource
4021292 VUID
N0000148729 NUI
D03693 KEGG_DRUG
C0908935 UMLSCUI
CHEBI:291342 CHEBI
CHEMBL1172 ChEMBL_ID
DB00967 DRUGBANK_ID
C121345 MESH_SUPPLEMENTAL_RECORD_UI
124087 PUBCHEM_CID
7157 IUPHAR_LIGAND_ID
7817 INN_ID
FVF865388R UNII
275635 RXNORM
16243 MMSL
42606 MMSL
51632 MMSL
83662 MMSL
d04785 MMSL
009081 NDDF
134506008 SNOMEDCT_US
396015008 SNOMEDCT_US
4021292 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 21695-815 TABLET, FILM COATED 5 mg ORAL NDA 23 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 42291-240 TABLET 5 mg ORAL ANDA 26 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 50090-0765 TABLET, FILM COATED 5 mg ORAL NDA 29 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3975 TABLET 5 mg ORAL ANDA 30 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-4794 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 54868-4624 TABLET, FILM COATED 5 mg ORAL NDA 12 sections
Clarinex-D 12 Hour HUMAN PRESCRIPTION DRUG LABEL 2 54868-5708 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 29 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 55111-360 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 55111-551 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 26 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 62250-619 TABLET 5 mg ORAL ANDA 25 sections
Desloratadine Human Prescription Drug Label 1 62756-523 TABLET, FILM COATED 5 mg ORAL ANDA 28 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 68180-153 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 69543-107 TABLET 5 mg ORAL ANDA 29 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1000 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 78206-119 TABLET, FILM COATED 5 mg ORAL NDA 30 sections
CLARINEX-D 12 HOUR HUMAN PRESCRIPTION DRUG LABEL 2 78206-120 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 29 sections